Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 6;15(12):e50017.
doi: 10.7759/cureus.50017. eCollection 2023 Dec.

Myasthenia Gravis: A Systematic Review

Affiliations
Review

Myasthenia Gravis: A Systematic Review

Aneesh K Mishra et al. Cureus. .

Abstract

Myasthenia gravis (MG), a rare disease, is the most common neuromuscular junction problem. It's the quintessential autoimmune disease with ocular, bulbar, respiratory, axial, and limb muscles exhibiting a typical fatigable weakening due to the development of antibodies against the acetylcholine receptor (AChR). Infections, stress, surgeries, thymus gland anomalies, and pharmaceutical side effects can also cause it. Ocular symptoms are initially experienced by most of the sufferers. The majority of the sufferers will go through at least one episode of symptom exacerbation during their illness. The immune system in MG interferes with nerve-muscle communication, causing muscles to become weak and tired quickly. The actual cause is not yet known, but a problem in the thymus gland may be the cause. In a person suffering from this disease, the size of the thymus becomes larger than normal, which is also called thymic hyperplasia. It is more common for women to have early-onset MG (EOMG) than for males to have late-onset MG (LOMG). Merely clinical evidence, encompassing the patients' medical history and physical indications of fluctuating muscle weakness in a specific region, is utilized to diagnose MG. Complementary diagnostic procedures and lab techniques aid in confirming the synaptic dysfunction and characterizing its kind and degree. Early diagnosis and the availability of effective treatments have reduced the burden of severe impairment and high mortality previously associated with MG. Current immunomodulation-based therapies come with side effects brought on by persistent immune suppression. Improved knowledge of this relatively uncommon but curable condition is required among primary carers. The objective of this review is to provide information about MG and to help people recognize its symptoms and start treatment without panic so that the progression of this disease can be stopped and complications can be avoided.

Keywords: auto-antibody; myasthenic crisis; neuromuscular junction; plasmapheresis; thymectomy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. The process by which the study articles were selected.

References

    1. An update on myasthenia gravis [Article in Spanish] Martínez Torre S, Gómez Molinero I, Martínez Girón R. Semergen. 2018;44:351–354. - PubMed
    1. Generalized myasthenia gravis: classification, clinical Presentation, natural History, and epidemiology. Hehir MK, Silvestri NJ. Neurol Clin. 2018;36:253–260. - PubMed
    1. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. Herr KJ, Shen SP, Liu Y, Yang CC, Tang CH. Front Neurol. 2023;14:1203679. - PMC - PubMed
    1. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Lancet Neurol. 2022;21:176–188. - PubMed
    1. Lifetime course of myasthenia gravis. Grob D, Brunner N, Namba T, Pagala M. Muscle Nerve. 2008;37:141–149. - PubMed

LinkOut - more resources